

Resource Summary Report

Generated by [SPARC SAWG](#) on Aug 10, 2026

Sigma-Aldrich

RRID:SCR_008988

Type: Tool

Proper Citation

Sigma-Aldrich (RRID:SCR_008988)

Resource Information

URL: <http://www.sigmaaldrich.com>

Proper Citation: Sigma-Aldrich (RRID:SCR_008988)

Description: American chemical, life science and biotechnology company owned by Merck KGaA. Merger of Sigma Chemical Company and Aldrich Chemical Company. Provides organic and inorganic chemicals, building blocks, reagents, advanced materials and stable isotopes for chemical synthesis, medicinal chemistry and materials science, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, proteins, peptides, amino acids and their derivatives.

Synonyms: Aldrich, Sigma, Merck KGaA, Merck, Sigma Aldrich

Resource Type: commercial organization

Keywords: Commercial, organization, chemical, life science, biotechnology, company, Merck, reagent

Resource Name: Sigma-Aldrich

Resource ID: SCR_008988

Alternate IDs: nlx_152460

Record Creation Time: 20220129T080250+0000

Record Last Update: 20260808T185919+0000

Ratings and Alerts

No rating or validation information has been found for Sigma-Aldrich.

No alerts have been found for Sigma-Aldrich.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 140605 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Sreekumar A, et al. (2026) Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy. *Cancer discovery*, 16(4), 781.

Lara Castillo NA, et al. (2026) Exercise beneficially reshapes fasted rat skeletal muscle involving the combined action of β -hydroxybutyrate and palmitoleic acid. *American journal of physiology. Cell physiology*, 330(4), C1006.

Ravegnini G, et al. (2026) Identification of MBT3T as a new effective therapeutic option in imatinib-resistant gastrointestinal stromal tumors (GISTs). *Journal of experimental & clinical cancer research : CR*, 45(1).

Chen K, et al. (2026) Identification of a distinct cluster of LY6E+ macrophages in esophageal squamous cell carcinoma: functional phenotype, spatial interaction, and prognostic significance. *British journal of cancer*, 135(3), 382.

Misra R, et al. (2026) Dengue protease-mediated activation and polarization of macrophages. *International journal of biological macromolecules*, 365, 152322.

Sinyavskiy S, et al. (2026) Benzo[e][1,2,4]triazolo[1,5-c][1,2,3]triazines: Design, Synthesis, and Cytotoxic Effects. *Chemistry & biodiversity*, 23(6), e71416.

Peirano E, et al. (2026) Trio analysis in dystonia identifies de novo KLC1 variants in a kinesinopathy with distinct motor and neurodevelopmental features. *EBioMedicine*, 129, 106358.

Hohaus N, et al. (2026) Synaptic Ca²⁺ channels and neurexins are linked through direct and indirect binding complexes. *Scientific reports*, 16(1).

Noronha-Matos JB, et al. (2026) Blockage of the peri-synaptic Schwann cell nicotinic $\alpha 7$ receptor inhibitory drive increases the neuromuscular performance in rats with experimental autoimmune Myasthenia gravis: repurposing dipyridamole usage in myasthenics. *Neuropharmacology*, 284, 110775.

Kandel R, et al. (2026) Transcriptomics reveal dysregulated genes during folic acid-induced acute injury and fibrosis in kidney and their attenuation by antioxidant N-acetyl cysteine. *American journal of physiology. Cell physiology*, 331(1), C177.

Bruzina AS, et al. (2026) Loss of ovarian hormones modulates sex-specific metabolic adaptations to volumetric muscle loss. *American journal of physiology. Cell physiology*, 331(1), C117.

Martin A, et al. (2026) Generalizable, high-throughput image analysis of subcellular structures using dispersion indices. *iScience*, 29(4), 115371.

Monteiro AC, et al. (2026) OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer. *Cancer research communications*, 6(1), 85.

Heider S, et al. (2026) Bone marrow adipose tissue mass and dipeptidyl peptidase-4 link aging and metabolic health to biomarkers of bone turnover. *American journal of physiology. Endocrinology and metabolism*, 330(4), E411.

Savoca A, et al. (2026) Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors. *Molecular cancer therapeutics*, 25(7), 1157.

Li H, et al. (2026) PDZRN4 suppresses lung adenocarcinoma progression via inhibiting ubiquitin-mediated HIF-1A degradation. *Oncogene*, 45(4), 577.

Ge X, et al. (2026) PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition. *Cancer research*, 86(15), 3819.

Ziegler Y, et al. (2026) JAK/STAT1-interferon-ISGylation networks in breast cancer resistance to inhibitors of FOXM1 and CDK4/6. *NPJ breast cancer*, 12(1).

Vilarrubi A, et al. (2026) SMARCB1 Deficiency in Tumors Confers a Vulnerability to H3K27 Demethylase Inhibitors via Autophagy Disruption. *Cancer research*.

Dhakal S, et al. (2026) AXL Kinase Inhibition Promotes Cytosolic DNA Sensor cGAS Activity and Sensitizes Poorly Immunogenic Tumors to Chemo-Immunotherapy. *Molecular cancer therapeutics*, 25(5), 745.